Search clinical trials for: NBI-921352

Total 2487 results

Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Healthy

Germany
University of Nottingham

Completed

HI-Light Pilot Trial for Vitiligo: Hand Held NB-UVB for Early or Focal Vitiligo at Home (HI-Light)

Vitiligo

United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Boehringer Ingelheim

Completed

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Neoplasms

Spain, United States, United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Healthy

Germany
Masonic Cancer Center, University of Minnesota

Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Lymphoma | Follicular Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous... and other conditions

United States
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Cairo University

Recruiting

Effect of Nano-Bio Fusion Gel on Palatal Wound Healing After Free Gingival Graft Harvest.

Free Gingival Graft

Egypt
Massachusetts General Hospital
Spaulding Rehabilitation Hospital

Completed

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

Traumatic Brain Injury | Major Depressive Disorder

United States
Columbia University

Completed

Family Nurture Intervention, A Group Model in Connecticut

Behavior Problem | Family Conflict | Development Delay | Emotional Disturbance

United States
Asfendiyarov Kazakh National Medical University

Completed

Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration Patients

Age-Related Macular Degeneration

Kazakhstan
AIDS Healthcare Foundation
Ganeden Biotech, Inc.

Completed

A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

HIV Infection | Gastrointestinal Symptoms

United States
The University of Hong Kong

Unknown

Mindfulness-based Intervention for Postnatal Depression

Postnatal Depression

Hong Kong
University of Miami

Completed

Mindfulness Training for Medical Personnel

Stress | Burnout, Professional

United States
Eleven Biotherapeutics

Completed

A Multi-Center Study Subjects With Dry Eye Syndrome (EBI)

Dry Eye Syndrome

United States
Mayo Clinic

Completed

Molecular Breast Imaging in Patients With a History of Bloody Nipple Discharge

Breast Cancer | Bloody Nipple Discharge

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Healthy

Germany
Clinique Romande de Readaptation

Active, not recruiting

Validation of an Ecological Organization and Problem Solving Test (TEM-PRO) in Vocational Rehabilitation (TEM-PRO)

TBI (Traumatic Brain Injury)

Switzerland
Nexstim Ltd

Completed

Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial (NICHE)

Stroke

United States
Columbia University

Completed

Stamford Group Family Nurture Intervention

Developmental Delay | Behavior Problem | Emotional Disturbances | Family Conflict

United States
Duke University
Monteris Medical

Withdrawn

LITT Palliative Treatment for Patients With Malignant Gliomas

Glioblastoma | Malignant Glioma of Brain

United States
Centre Hospitalier Universitaire de Saint Etienne
Fondation de l'Avenir

Terminated

Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery (OBESITE)

Obesity | Bariatric Surgery

France
Welichem Biotech Inc.

Completed

A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks (134993)

Psoriasis
Mayo Clinic

Completed

New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer

Breast Cancer

United States
Welichem Biotech Inc.

Completed

Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream

Dermatitis, Atopic

Canada
Rabin Medical Center

Unknown

The Role of Calcipotriol as Radioprotector of Skin

Radiodermatitis

Israel
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Institutes of Health (NIH)

Not yet recruiting

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Cervical Cancer
Boehringer Ingelheim

Not yet recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy
Boehringer Ingelheim

Recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

Diabetic Nephropathies

Spain, Australia, United States, Canada, China, Japan, Malaysia, United Kingdom, Mexico, Portugal, Denmark, Hong Kong, Poland, New Zealand, Argentina, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

Healthy

Japan
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Healthy
Boehringer Ingelheim

Completed

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Arthritis, Rheumatoid

United States, Poland
Boehringer Ingelheim

Recruiting

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)

Neoplasms

United States, Belgium, Netherlands, Germany, Spain, Australia, United Kingdom, Japan, France, Singapore, Hungary
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Psoriasis

United States, Canada, Germany
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim

Recruiting

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Bronchiectasis

Belgium, Germany, Korea, Republic of, Australia, Spain, Netherlands, Denmark, Bulgaria, Japan, Turkey, United States, Czechia, France, Hungary, Italy, Latvia, Poland, Canada, Portugal
Boehringer Ingelheim

Active, not recruiting

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Healthy | Obesity

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Healthy

Germany

3

Subscribe